Pharvaris

IPO

Pioneering Science for Patient Choice

Public · Zug, Switzerland · Founded 2015 · $216.0M raised

Headquarters
Zug
Employees
51–200
Founded
2015
Business Model
B2B
Total Funding
$216.0M
Last Round
$70.0M Private EquityJun 2023
Rounds
3
Type
Public

About

Pharvaris is a late-stage biopharmaceutical company developing novel oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks. Its lead asset, deucrictibant, is in two pivotal Phase 3 trials (CHAPTER-3 for prophylaxis and RAPIDe-3 for on-demand treatment), aiming to deliver injectable-like efficacy with the convenience of oral administration.

Summary

Pharvaris is a Biotech company based in Zug, Switzerland, founded in 2015. It has raised $216.0M in total across 3 rounds, most recently a $70.0M Private Equity round in Jun 2023.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Private EquityPrivate PlacementJun 2023
$70.0M

Sign up to see all 4 rounds

Series B through Private Equity — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Pharvaris on Indexed.vc
<a href="https://indexed.vc/companies/pharvaris"><img src="https://indexed.vc/api/badge/company/pharvaris" alt="Pharvaris on Indexed.vc" width="260" height="76" /></a>